On Tuesday, President Donald Trump announced a deal with upstate New York company Eastman Kodak in an effort to start bringing back vital pharmaceutical drug ingredient manufacturing to the United States, an apparent response to strains emphasized during the China-originated novel coronavirus pandemic.
According to a recent Wall Street Journal report, China accounted for 46% of the share of active pharmaceutical ingredient exports in 2019; the U.S. accounted for 10%.
.png)
.png)
